Biotech Startup Mekonos Raises Oversubscribed $25 Million Round To Overcome Pharma Industry'S Cell & Gene Therapy Delivery Hurdles

Nov 09, 2021•over 3 years ago

Amount Raised

$25 Million

San Francisco

Description

Mekonos, a biotech company building the future of cell therapies on a chip, has raised $25M in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, a division of PEAK6 Investments. New institutional and strategic investors, including Section 32, Sands Capital, TDK Ventures, and the venture arm of Debiopharm, and previous investors, including Novartis Pharma AG (dRx Capital) and Elementum Ventures, also joined in the funding round that will support Mekonos' next stages in product development and commercialization.

Company Information

Company

Mekonos

Location

San Francisco, California, United States

About

Mekonos is an enabling technology company transforming synthetic biology and personalized medicine. The company's SoC merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale. The company is headquartered in San Francisco, is backed by leading investors in both healthcare and technology, and is an alum of Berkeley Launch, Berkeley SkyDeck, Creative Destruction Lab, and named a 2018 Fierce 15 startup. For more information, please visit https://mekonos.com/technology. ### SOURCE Mekonos

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Biotech Startup Mekonos Raises Oversubscribed $25 Million Round To Overcome Pharma Industry'S Cell & Gene Therapy Delivery Hurdles

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information